An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16 Liya MaGen LiHong Ni Original Article Open access 12 October 2022 Pages: 431 - 444
A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL) Suja JohnsonChetan DhamneVikram Gota Original Article 17 October 2022 Pages: 445 - 453
Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways Hai LinFengjie SunZhiyuan Fang Original Article 17 October 2022 Pages: 455 - 465
Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab Basma M. SharafAlexander D. GiddeyNelson C. Soares Original Article 20 October 2022 Pages: 467 - 488
Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia Weizhe JianJunsheng XueTianyan Zhou Original Article 22 October 2022 Pages: 489 - 497
Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats Xin-mei LiYuan-dong ZhengXing-xing Diao Original Article 25 October 2022 Pages: 499 - 510
Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study Naoki KotaniJustin J. WilkinsPascal Chanu Original Article Open access 28 October 2022 Pages: 511 - 521
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors Shigehisa KitanoYutaka FujiwaraNoboru Yamamoto Short Communication 26 October 2022 Pages: 523 - 529
